ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

HEMO Hemogenyx Pharmaceuticals Plc

1.37
0.031 (2.32%)
Last Updated: 09:40:44
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Hemogenyx Pharmaceuticals Plc LSE:HEMO London Ordinary Share GB00BYX3WZ24 ORD GBP0.01
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.031 2.32% 1.37 1.352 1.398 1.398 1.37 1.40 2,050,974 09:40:44
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Finance Services 0 -6.69M -0.0059 -2.32 15.65M
Hemogenyx Pharmaceuticals Plc is listed in the Finance Services sector of the London Stock Exchange with ticker HEMO. The last closing price for Hemogenyx Pharmaceuticals was 1.34p. Over the last year, Hemogenyx Pharmaceuticals shares have traded in a share price range of 1.275p to 6.30p.

Hemogenyx Pharmaceuticals currently has 1,141,999,321 shares in issue. The market capitalisation of Hemogenyx Pharmaceuticals is £15.65 million. Hemogenyx Pharmaceuticals has a price to earnings ratio (PE ratio) of -2.32.

Hemogenyx Pharmaceuticals Share Discussion Threads

Showing 351 to 371 of 13450 messages
Chat Pages: Latest  22  21  20  19  18  17  16  15  14  13  12  11  Older
DateSubjectAuthorDiscuss
28/2/2018
15:16
It's not AIM! dyor!
renalrod
28/2/2018
14:55
So many people sell on the downward spike but well down from highs. Bail on a spike up not a spike down but most on AIM are not happy unless they are losing money.
dave4545
28/2/2018
14:44
Yawn. Another aim sucker. Touching 7p two days ago. Lots more long term holders.
sidjameslaugh
28/2/2018
14:41
Could test 4p by close M
jimmyhoffa262
28/2/2018
12:52
HEMO in talks and working with several major pharmas Worth a watchRNS EXCLUSIVE: HemoGenyx release successful CDX Antibody first data results youtu.be/3z6IKgPik0s via @YouTube #HEMO
tidy 2
28/2/2018
12:41
will be interesting to see the results of mice tests summer 2019.

bit of a wait, but could be worth it.gl

runwaypaul
28/2/2018
11:52
Sells dried up..next leg up me thinks, primed
tsmith2
28/2/2018
11:51
This could be a huge Multibagger this year. If confirmation of a big player coming in is announced then this will pay the mortgage
ernestsyngen
28/2/2018
09:00
runwaypaul28 Feb '18 - 08:08 - 341 of 345

page 8

2015

2016

No mention of

First data results have shown that CDX bi-specific antibodies are capable of attacking and eliminating the blood cancer Acute Myelogenous Leukemia (AML) in vitro. Using these new humanised mice the Company is confident that it should be able to demonstrate that its lead product, CDX bi-specific antibodies, are effective in the treatment of (AML).

cottoner
28/2/2018
08:51
i reckon that hemo should be at 10p and imm at 200p
it's just dilly-dallying till we finally get there.

imm and hemo are the best pharam stories going.

andrbea
28/2/2018
08:46
v v little stock
tsmith2
28/2/2018
08:16
You bought back then? What price?
goodbloke1
28/2/2018
08:08
page 8

2015

2016

runwaypaul
28/2/2018
08:07
says it here



cant see how this is new news?

runwaypaul
28/2/2018
07:58
now you are talking b*llcks..I hold both and think both potentially offer exceptional multi baggers
tsmith2
28/2/2018
07:22
Think I'll wait for sub 3.5p entry it's coming
jimmyhoffa262
28/2/2018
07:08
I’m sure that was yesterday’s prediction:)
sidjameslaugh
28/2/2018
06:30
Where in the IPO document does it say?

'First data results have shown that CDX bi-specific antibodies are capable of attacking and eliminating the blood cancer Acute Myelogenous Leukemia (AML) in vitro. Using these new humanised mice the Company is confident that it should be able to demonstrate that its lead product, CDX bi-specific antibodies, are effective in the treatment of (AML).'


As the HEMO CEO stated in the RNS

Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx, commented: "We are hugely excited by the first solid data that we've received testing the efficacy of CDX antibodies against Acute Myelogenous Leukemia. The results which show that they can attack and eliminate AML cells is a true breakthrough and a significant development in our process of developing CDX to become a universally available conditioning product for patients undergoing bone marrow transplants as a treatment for serious blood diseases.

cottoner
27/2/2018
23:31
Maybe they were retweeting.....
runwaypaul
27/2/2018
23:30
This news appears to have been mentioned in the ipo document.it was released in 2016?
runwaypaul
27/2/2018
21:37
Going to be a bagger all year
ernestsyngen
Chat Pages: Latest  22  21  20  19  18  17  16  15  14  13  12  11  Older